Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.

Daniel Shao-Weng Tan,Geoffrey Liu,Zheng-Yi Zhou,James E Signorovitch,Antonio Araujo,Jie Zhang,Xiaopeng Cai

doi:10.1200/jco.2015.33.15_suppl.8058

Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.

Daniel Shao-Weng Tan, Geoffrey Liu + Show 5 more

https://doi.org/10.1200/jco.2015.33.15_suppl.8058

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2015

Affiliation: National Cancer Centre Singapore, Princess Margaret Cancer Centre, Analysis Group (United States), Centro Hospitalar do Porto, Tris Pharma (United States)

#Metastatic Non-small Cell Lung Cancer #Ceritinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

8058 Background: Ceritinib (CER) has been studied in previously treated, crizotinib (CRZ)-naive patients (pts) in two clinical trials (ASCEND-1: NCT01283516; ASCEND-3: NCT01685138). No randomized c...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.